Pimobendan Capsule, which is a drug used to treat cardiovascular diseases and belongs to phosphodiesterase III (PDE3) inhibitors. In the drug classification, it belongs to the category of anti heart failure drugs, which improve heart function by enhancing myocardial contractility and vasodilation. The chemical name of Pimobedan is 6- [2- (4-methoxyphenyl) -1H-benzimidazol-5-yl] -5-methyl-4,5-dihydro-3 (2H) - pyridazinone, with a molecular formula of C19H18N4O2, CAS 74150-27-9, and a molecular weight of 334.37. It is a white to slightly yellow crystalline powder that is almost insoluble in water or ethyl, but has a certain solubility in organic solvents, such as being freely soluble in formic acid or acetic acid, and slightly soluble in ethanol or methanol. There are usually made by mixing pimobedan with suitable excipients to form a capsule form for oral administration.
Our product
Additional information of chemical compound:
Our Product
Pimobendan+. COA
Pharmacokinetic properties
Absorption
After oral administration of Pimobendan capsules, the drug is absorbed in the gastrointestinal tract. The absorption rate and degree may be influenced by various factors, such as food intake, pH value of the gastrointestinal tract, etc. Generally speaking, the blood concentration of pimobedan reaches its peak about 0.8 hours after oral administration.
Distribution
Pimobedan is widely distributed in the body and has a high binding rate with plasma proteins. It can enter myocardial cells and vascular smooth muscle cells, exerting its pharmacological effects.
Metabolism
Pimobedan is metabolized in the liver, and its active metabolite (UD-CG212) has a stronger effect than Pimobedan itself. Metabolites are mainly excreted through bile into the digestive tract and excreted with feces.
Excretion
The excretion of pimobedan and its metabolites is mainly through feces, with a small amount possibly excreted through urine. Its elimination half-life is relatively short, with a t1/2 of about 1 hour for healthy individuals after oral administration. After continuous application for one week, there was no accumulation of blood concentration.
Drug interactions and precautions
Drug interactions
Interaction with digitalis drugs
When combined with digitalis drugs, it may enhance the positive inotropic effect of digitalis and increase the risk of arrhythmia. Therefore, close monitoring of the patient's electrocardiogram and blood drug concentration is necessary when using combination therapy.
Interaction with calcium channel blockers
Calcium channel blockers may weaken the positive inotropic effect of pimobedan, while pimobedan may also affect the efficacy of calcium channel blockers. Therefore, caution should be exercised in adjusting the dosage when using combination therapy.
Interactions with other drugs
It may also interact with other drugs, such as beta blockers, angiotensin-converting enzyme inhibitors, etc. When using combination therapy, it is necessary to comprehensively consider the mechanism of action and adverse reactions of the drug, in order to avoid adverse reactions or reduce the efficacy.
Precautions
Pre medication evaluation
Before using Pimobendan capsules, it is necessary to conduct a comprehensive physical examination of the patient, including cardiac function assessment, liver and kidney function examination, etc., to determine whether the patient is suitable for using the drug.
Medication process monitoring
During the medication process, it is necessary to closely observe the patient's reactions and changes in their condition, regularly measure vital signs such as heart rate and blood pressure, and adjust the treatment plan in a timely manner. If serious adverse reactions occur, the medication should be stopped promptly and corresponding treatment measures should be taken.
Medication for special populations
For special populations such as elderly patients and patients with liver and kidney dysfunction, it is necessary to carefully adjust the dosage and closely monitor the adverse reactions of the medication when using product.
The common synthesis methods of pimobedan mainly involve multi-step organic chemical reactions. The following is an overview of one of the more typical synthesis routes:
Starting materials and preliminary reactions
Starting materials: The synthesis of pimobedan usually starts with specific organic compounds such as chlorobenzene or acetanilide. These raw materials undergo a series of chemical reactions to gradually construct the molecular structure of pimobedan.
Preliminary reaction: The starting material first undergoes steps such as acetylation, nitration, bromination, etc. to generate intermediate compounds. These reactions typically require specific catalysts, solvents, and reaction conditions to be carried out.
Conversion of intermediate compounds
Preparation of intermediate compounds: Through further chemical reactions such as nucleophilic substitution reactions, hydrolysis decarboxylation reactions, etc., the intermediate compounds generated by the initial reaction are converted into more active intermediates.
Purification of intermediates: During the conversion process, it may be necessary to purify the intermediates to remove impurities and improve the purity of the product. Purification methods usually include extraction, recrystallization, column chromatography, etc.
Key steps and reaction conditions
Key steps: In the synthesis of pimobedan, there are some key steps that determine the quality and yield of the final product. For example, coupling reactions, ester hydrolysis reactions, and decarboxylation reactions between certain intermediate compounds.
Reaction conditions: These key steps typically require specific reaction conditions, such as temperature, pressure, catalyst type and dosage. The optimization of reaction conditions is crucial for improving the yield and purity of the product.
Synthesis and purification of the final product
The synthesis of the final product: After a series of chemical reactions, Pimobendn is finally produced. During this process, it may be necessary to fine tune the reaction conditions to ensure the quality and yield of the product.
Purification of the pimobendan capsule: The generated pimobendn usually requires purification treatment to remove residual impurities and catalyst. Purification methods may include recrystallization, column chromatography, etc.
development history
The development history can be traced back to the early exploration of drug development, which has gone through basic research, clinical validation, and widespread application, gradually becoming an important drug in the field of cardiovascular disease treatment.
1. Early research and mechanism exploration (1980s to 1990s)
The development of Pimobendn began in the 1980s, with scientists dedicated to finding drugs that combine positive inotropic effects and vasodilatory effects. Its molecular structure is a benzimidazole pyridazine derivative, which functions through a dual mechanism: on the one hand, it acts as a phosphodiesterase III (PDE3) inhibitor, reducing the degradation of cyclic adenosine monophosphate (cAMP), increasing intracellular cAMP concentration, and enhancing myocardial contractility; On the other hand, as a calcium sensitizer, it directly increases the sensitivity of myocardial contractile proteins to calcium ions, improving myocardial contraction efficiency. This unique mechanism enhances myocardial contractility while avoiding the risk of arrhythmia that may be caused by traditional positive inotropic drugs.
Early animal experiments have confirmed that pimobedan can significantly improve cardiac function indicators in canine heart failur models, such as increasing left ventricular ejection fraction (LVEF), reducing left ventricular end diastolic pressure, and reducing pulmonary and systemic vascular resistance. These research findings have laid the foundation for their subsequent clinical applications.
2. Clinical Application and Indications Expansion (1999 present)
In 1999, Pimobedan was approved in Europe for the treatment of congestive heart failur in dogs, marking its official entry into the clinical application stage. In the initial stage, it mainly targets heart failur secondary to dilated cardiomyopathy (DCM) and chronic mitral valve insufficiency (CMVI). By enhancing myocardial contractility and reducing pre - and post cardiac load, it significantly improves the quality of life and prognosis of affected dogs.
With the deepening of clinical research, the indications of pimobedan have gradually expanded to include mucinous/degenerative mitral valve disease (MMVD/DMVD). Research has shown that the drug can alleviate left ventricular burden caused by mitral valve insufficiency, improve cardiac pumping function, and delay disease progression. In addition, pimobedan has been explored for intervention in the pre heart failur stage or preclinical heart failur stage, as well as in combination therapy with angiotensin-converting enzyme inhibitors (ACEIs), in order to further improve cardiac function through multi-target action.
3. Formulation improvement and safety research (from the beginning of the 21st century to present)
To improve drug bioavailability and patient compliance, the dosage form of pimobedan is continuously optimized. At present, there are mainly capsules and tablets on the market, among which capsules can reduce gastrointestinal irritation and improve drug stability. Food has a significant impact on the oral bioavailability of pimobedan, therefore it is recommended to administer it on an empty stomach to ensure efficacy.
Safety studies have shown that pimobendn has fewer adverse reactions, mainly gastrointestinal intolerance. However, the drug is contraindicated in dogs with known outflow tract obstruction (such as aortic valve stenosis) as it may exacerbate the symptoms of obstruction. In addition, pimobedan has not been approved for use in cats, and although some retrospective studies have shown good tolerability in cats, there is a lack of clear evidence of efficacy.
Future prospects and research directions
With a deeper understanding of the mechanism of action of pimobendn, future research will focus on its potential application in early intervention of heart disease. For example, exploring the impact of pimobendn on preclinical survival time in dogs with occult DCM or DMVD stage B2, as well as its combination therapy with other drugs. In addition, the application of new drug delivery systems such as nanotechnology may further enhance the targeting and bioavailability of pimobendn, reducing side effects.
Market and sales situation
Manufacturers and sales channels
Produced by multiple pharmaceutical companies, products from different manufacturers may have differences in quality, price, specifications, and other aspects. In foreign countries, formulations produced by companies such as Boehringer Ingelheim are more common. It is sold through channels such as veterinary clinics, pet hospitals, and drug distributors.
Market prices and competition situation
Market prices vary due to factors such as region, manufacturer, specifications, etc. In the market, there is competition among multiple brands for sales. Consumers can consider their own needs and budget when making a choice, while also paying attention to choosing legitimate channels to ensure the quality and safety of drugs.
Market Trends and Prospects
With the continuous development of the pet market and people's increasing attention to pet health, the incidence rate of cardiovascular diseases in dogs is also gradually rising. Therefore, the market demand in the veterinary field is expected to continue to increase. In the future, with the continuous advancement of pharmaceutical technology and the deepening of clinical applications, the market prospects of Pimobendan capsules will be even broader.
FAQ
1. What is the main purpose of Pimobendan (Pimobendan) capsules?
It is a veterinary (mainly for dogs) prescription drug used to treat congestive heart failure caused by dilated cardiomyopathy (DMD) or degenerative mitral valve disease (MMVD). It improves cardiac function by enhancing cardiac contractility and dilating blood vessels.
2. When should this medication be started or stopped?
Usually, this medication is administered when the dog shows clinical symptoms of heart failure (such as coughing, breathing difficulties, and decreased activity). It should be started after a veterinary diagnosis. Never stop the medication on your own. Any dosage adjustments or discontinuation must be strictly followed by the veterinarian; otherwise, the condition may deteriorate rapidly.
3. What are the important precautions to follow during medication use?
It is necessary to regularly monitor the kidney function and heart condition of the dog; it may be used in combination with other drugs (such as diuretics, ACEI); the medication should be administered strictly according to the prescribed dosage and schedule (usually fed before meals); observe for any side effects such as loss of appetite, diarrhea or weakness and inform the veterinarian promptly.
4. How should the drugs be stored?
It should be stored in a sealed container at room temperature (typically recommended to be between 15-25°C), in a dry and dark place, out of reach of children and pets, and ensure the package is intact.
Hot Tags: pimobendan capsule, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale